Broad Institute
OCTOBER 4, 2023
Related links Merkin Prize Inaugural Merkin Prize in Biomedical Technology awarded to Dr. Marvin Caruthers for developing technology that efficiently synthesizes DNA The inaugural Richard N. Caruthers was announced as the winner in June for his development, in 1981, of an efficient, automated technology for synthesizing DNA.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The UK, and specifically Wales, has been hugely supportive of life sciences and building a highly collaborative network.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
JUNE 11, 2024
And unlike traditional DNA sequencers, which parse genetic material by breaking it up into fragments and interpreting it chunk-by-chunk, a nanopore device unspools a long strand of DNA and reads it all at once. A scientist can isolate DNA and load up a flow cell in fifteen minutes. Nanopore devices work incredibly fast.
The Pharma Data
OCTOBER 21, 2020
The long-acting regimen of cabotegravir and rilpivirine is an investigational regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). Shionogi joined in October 2012.
Drug Discovery World
JULY 18, 2023
Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g.,
New Drug Approvals
JANUARY 9, 2024
May 30; 31(11): 2498-510, 2012). CDK7 also plays a role in transcription and possibly in DNA repair. The trimeric Cak complex CDK7/CyclinH/MATl is also a component of TFIIH, the general transcription/DNA repair factor IIH (Morgan, DO., Mar 23;25(6):839-50. 2007; Ganuza et al., 13, 261-91, 1997). 1004-1014, 2004). Cancer Res.
Drug Target Review
AUGUST 9, 2023
The specific proteins found in these aggregates can vary, but approximately 95 percent of ALS patients and 50 percent of FTD patients develop aggregates containing the TDP-43 protein (short for tar DNA binding protein 43). 14 TDP-43 is a DNA and RNA binding protein that regulates the expression and splicing of several target transcripts.
Expert insights. Personalized for you.
52 
Let's personalize your content